BNP Paribas Financial Markets’s Vanda Pharmaceuticals VNDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$114K Buy
16,495
+604
+4% +$4.66K ﹤0.01% 4308
2025
Q4
$140K Sell
15,891
-49,644
-76% -$273K ﹤0.01% 4210
2025
Q3
$327K Buy
65,535
+56,556
+630% +$262K ﹤0.01% 3778
2025
Q2
$42.4K Sell
8,979
-23,201
-72% -$101K ﹤0.01% 4319
2025
Q1
$148K Sell
32,180
-40,132
-55% -$187K ﹤0.01% 3876
2024
Q4
$346K Buy
72,312
+10,074
+16% +$48.4K ﹤0.01% 3532
2024
Q3
$292K Buy
62,238
+57,393
+1,185% +$308K ﹤0.01% 3088
2024
Q2
$27.4K Sell
4,845
-96,518
-95% -$498K ﹤0.01% 3593
2024
Q1
$417K Buy
101,363
+41,767
+70% +$167K ﹤0.01% 2946
2023
Q4
$251K Buy
59,596
+20,206
+51% +$81.5K ﹤0.01% 3117
2023
Q3
$170K Sell
39,390
-38,532
-49% -$214K ﹤0.01% 3153
2023
Q2
$514K Sell
77,922
-84,080
-52% -$539K ﹤0.01% 2568
2023
Q1
$1.1M Buy
162,002
+90,573
+127% +$637K ﹤0.01% 2248
2022
Q4
$528K Sell
71,429
-12,529
-15% -$122K ﹤0.01% 2541
2022
Q3
$830K Buy
83,958
+63,512
+311% +$671K ﹤0.01% 2628
2022
Q2
$223K Sell
20,446
-3,862
-16% -$40K ﹤0.01% 3035
2022
Q1
$275K Sell
24,308
-11,701
-32% -$154K ﹤0.01% 3013
2021
Q4
$565K Sell
36,009
-29,704
-45% -$518K ﹤0.01% 2946
2021
Q3
$1.13M Buy
65,713
+36,663
+126% +$642K ﹤0.01% 2289
2021
Q2
$625K Sell
29,050
-1,057
-4% -$18.9K ﹤0.01% 2422
2021
Q1
$452K Buy
30,107
+886
+3% +$14.3K ﹤0.01% 2621
2020
Q4
$384K Buy
29,221
+15,490
+113% +$186K ﹤0.01% 2586
2020
Q3
$133K Sell
13,731
-45,192
-77% -$483K ﹤0.01% 2966
2020
Q2
$674K Buy
58,923
+28,625
+94% +$324K ﹤0.01% 1974
2020
Q1
$314K Buy
30,298
+18,471
+156% +$229K ﹤0.01% 2616
2019
Q4
$194K Buy
11,827
+3,635
+44% +$55K ﹤0.01% 2965
2019
Q3
$109K Buy
8,192
+2,458
+43% +$34.3K ﹤0.01% 3083
2019
Q2
$80.8K Sell
5,734
-4,952
-46% -$78.8K ﹤0.01% 3155
2019
Q1
$197K Buy
10,686
+10,669
+62,759% +$243K ﹤0.01% 2716
2018
Q4
$444 Sell
17
-1,686
-99% -$39.6K ﹤0.01% 4013
2018
Q3
$39.1K Hold
1,703
﹤0.01% 3150
2018
Q2
$32.4K Sell
1,703
-7,639
-82% -$128K ﹤0.01% 3299
2018
Q1
$157K Buy
9,342
+73
+0.8% +$1.22K ﹤0.01% 2935
2017
Q4
$141K Buy
9,269
+4,765
+106% +$70.7K ﹤0.01% 3132
2017
Q3
$80.6K Sell
4,504
-284
-6% -$4.75K ﹤0.01% 2902
2017
Q2
$78K Buy
4,788
+4,581
+2,213% +$66K ﹤0.01% 2942
2017
Q1
$2.9K Sell
207
-1,846
-90% -$26.3K ﹤0.01% 3438
2016
Q4
$32.7K Sell
2,053
-483
-19% -$7.76K ﹤0.01% 3005
2016
Q3
$42.2K Sell
2,536
-40,975
-94% -$552K ﹤0.01% 2505
2016
Q2
$487K Buy
43,511
+1,411
+3% +$13.7K ﹤0.01% 1523
2016
Q1
$352K Sell
42,100
-51,612
-55% -$424K ﹤0.01% 1306
2015
Q4
$872K Buy
93,712
+84,659
+935% +$845K ﹤0.01% 1155
2015
Q3
$102K Buy
9,053
+5,576
+160% +$68.2K ﹤0.01% 2379
2015
Q2
$44.1K Buy
3,477
+2,548
+274% +$27.5K ﹤0.01% 2570
2015
Q1
$8.64K Buy
+929
New +$10.5K ﹤0.01% 2833
2014
Q4
Sell
-2,032
Closed -$21.1K 3176
2014
Q3
$21.1K Buy
+2,032
New +$26.6K ﹤0.01% 3131
2014
Q1
Sell
-430
Closed -$5.34K 3819
2013
Q4
$5.34K Buy
+430
New +$4.32K ﹤0.01% 3056
2013
Q3
Sell
-12,078
Closed -$97.6K 2722
2013
Q2
$97.6K Buy
+12,078
New +$81.3K ﹤0.01% 2536

Other funds holding VNDA

BNP Paribas Financial Markets's VNDA Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Vanda Pharmaceuticals (VNDA) stake by 3.8% in Q1 2026, buying an estimated $4.66K and bringing the position to 16,495 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #4308.

BNP Paribas Financial Markets first reported a position in VNDA in Q2 2013 and has held it in 48 quarters since. The position peaked at $1.13M in Q3 2021. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • BNP Paribas Financial Markets held 16,495 shares of Vanda Pharmaceuticals worth $114K as of Q1 2026.
  • BNP Paribas Financial Markets bought 604 Vanda Pharmaceuticals shares in Q1 2026, an estimated $4.66K.
  • Vanda Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4308 holding.
  • BNP Paribas Financial Markets first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
  • BNP Paribas Financial Markets's Vanda Pharmaceuticals position peaked at $1.13M in Q3 2021.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.